TVS Eurogrip displays future-ready products at Bharat Mobility Global Expo 2024

New Delhi, 2nd February 2024: TVS Eurogrip, one of India’s leading manufacturers & exporters of two-wheeler, three-wheeler and Off-Highway Tyres, exhibited their flagship products in the two-wheeler & off-highway segments in an aesthetically designed stand at Bharat Mobility Global Expo 2024 being held at Pragati Maidan, New Delhi.

TVS Eurogrip

Commenting on the participation, Mr. P. Madhavan, Executive Vice President – Marketing & Sales, TVS Eurogrip said, “Bharat Mobility Global Expo 2024 has set the stage for India’s journey towards sustainable mobility. The expo has unlocked multitude of opportunities for the world and India to co-create and transform the future of automotive industry. Our exhibit showcases the latest in tyre technology and our world-class products. At TVS Eurogrip, we are all geared for new age mobility and are future ready.”

Bharat Mobility Global Expo features exhibits and events covering vehicles of the future, cutting-edge technologies in automotive components, electric vehicle battery and charging technologies, alternate powertrains, innovative and disruptive technologies. With more than 800 exhibitors and 50+ overseas players, the three-day expo from February 1st to 3rd expects participation of over 80,000 visitors.

TVS Eurogrip is at Stand No. 6, First floor – Hall 14.

Get ready to set the dance floors ablaze with these top 5 tracks from Vh1 Supersonic’s

Vh1 Supersonic artist, Major Lazer Soundsystem, an influential force in the world of electronic and dancehall music, has left an indelible mark on the global music scene. Major Lazer is a Jamaican-American electronic dance music and DJ trio, which includes record producer Diplo, and DJs Walshy Fire and Ape Drums. Known for their groovy beats, Diplo and Walshy of the trio have a strong and rooted connection with India. Did you know that Diplo, at the age of 20, moved to India to kickstart his career and Walshy has been open about his fondness for India’s cultural diversity and how it’s close to his heart.

 So, before we get to witness their magnificent live performance this month, let’s recap their Top 5 tracks!

spersonic

 1. Lean On: This Global smash was shot in India which was #1 in over 40 countries and has over 6.5 billion streams on Spotify alone. The catchy tune and energetic dance move along with traditional Indian props fueled a worldwide dance craze, with countless remixes and renditions emerging all over the world, including India.

 2. Cold Water: A melodic pop perfection, captivating hearts and topping charts, known for its summer vibes, making Major Lazer Soundsystem a household name. This is another chart-topping collaboration featuring Justin Bieber, racking up over 3.5 billion streams.

 3. Powerful: This song is an anthem of hope and unity, resonating with India’s diverse youth, finding power in music and community. This is an uplifting anthem with over 600 million streams and was initially planned to be the lead single from the album but was scrapped in favor of Lean On.

mazer

 4. Light It Up: For this song, the artists crafted 50 texture effects along with custom algorithms to implement them, creating a CG environment complete with lighting, camera setups, and textures. Subsequently, the film underwent re-editing to synchronize with Major Lazer’s “Light it Up” track before being shared online, accumulating over 100 million views.

 5. Know No Better: Hip-hop infused pop fusion, showcasing Major Lazer Soundsystem’s genre- bending prowess, attracting a wider audience in India. This song features an all-star lineup and catchy beats, with over 1.5 billion streams.

National Skills Awards for Eminence Shine Bright

New Delhi: Electronics Sector Skills Council of India (ESSCI) orchestrated a splendid ceremony to confer the ‘National Skills Awards for Eminence’ at Bharat Mandapam, Pragati Maidan, New Delhi, coinciding with the Electronics Expo 2024. The event, graced by the esteemed presence of Shri Piyush Goyal, Union Minister of Commerce & Industry, Consumer Affairs, Food & Public Distribution & Textiles, witnessed the recognition of outstanding achievers in different categories.

 The objective of the awards is to recognize outstanding contributions across various categories, honouring organizations and individuals for their exceptional efforts in furthering skill development and promoting excellence in India’s electronics sector. The awards ceremony aimed to highlight and celebrate key stakeholders driving innovation and nurturing skills in the industry.

award

 The Skilling Initiative of the Year award was conferred upon LG Electronics India Pvt Ltd.
The Education Initiative of the Year award was presented to SRM Institute of Science & Technology. Samsung India Electronics Pvt Ltd. was honoured with the CSR Initiative of the Year award. SFO Technologies Pvt Ltd. received the Business Eminence Award of the Year. The Emerging Global Organization of the Year award went to CP Plus. National Centre for Flexible Electronics, IIT Kanpur won the Incubation & Startup Initiative of the Year award. The Woman CSR Leader of the Year award was given to Aradhana Rai Gupta from Havells India Ltd. The accolade was conferred by Wilfredo Gonzales Vidal, Deputy Minister of Communications, Cuba.

 Padma Bhushan Dr Ajai Chowdhry, Founder of HCL & Chairman of EPIC foundation was honored with the prestigious “Lifetime Achievement Award” for his contribution to India’s electronics industry over the past four decades. This recognition serves as a testament to the remarkable contributions he has made for the growth of ESDM sector.

 The eminent winners were chosen for their phenomenal contributions to furthering skill development, education, corporate social responsibility, business excellence, global impact, and nurturing startups within electronics.

 Mr Amit Manwani, Chairman ESSCI said: “A skilled workforce is the most critical asset for
the electronics industry as we step into an era of rapid technological disruptions. Building a vast talent pool through training, upskilling and nurturing skills is crucial for India’s
electronics sector to innovate, expand globally and realize its full potential. At ESSCI, our
diverse skilling initiatives aim to create a culture of excellence by empowering individuals
and organizations with industry-relevant skills to succeed.”

 Sandeep Narula, Chairman of ESC said: “The electronics industry is a major economic
growth driver for India and to reap the benefits of the ‘Make in India’ initiative and for
indigenous manufacturing to flourish, a robust skill development strategy is crucial. Investing in creating an electronics skills ecosystem through industry collaborations, vocational training, and apprenticeships will build a future-ready workforce. This will drive innovation, efficiency, and competitiveness while opening doors for youth employment as the industry scales up across domains like communication systems, consumer electronics, strategic electronics, and medical electronics.” Mr. Gurmeet Singh, Executive Director, ESC was also present in the event to felicitate the winners.

“For India’s electronics sector to achieve its full potential, a skilled workforce is imperative.
ESSCI is proud to play a key role in helping develop industry-ready talent through our
diverse skilling initiatives. We aim to build a vast pool of skilled professionals who can take
the electronics industry into the future through their expertise. Upskilling existing talent and nurturing new skilled workers will be vital for the sector’s growth and to capitalize on the opportunities of a digitally transforming world. ESSCI remains dedicated to enabling a
culture of learning and excellence across electronics, empowering both individuals and
organizations.” said Dr Abhilasha Gaur, COO, ESSCI.

 ESSCI extends hearty congratulations to the deserving winners and remains committed to promoting skills and innovation in electronics. ESSCI also set up a stall at the expo to showcase skill initiatives bridging industry skill gaps. The stall highlighted the importance of hiring certified talent to attract and retain professionals. It addressed skill mismatches in recruitments regarding locations, roles and compensation expectations.

Hon’ble Prime Minister Shri Narendra Modi to launch power projects worth Rs 28,978 Crore

Bengaluru, 2nd February 2024: Hon’ble Prime Minister Shri Narendra Modi will dedicate to the Nation NTPC Darlipali Super Thermal Power Station (2×800 MW), NSPCL Rourkela PP-II Expansion Project (1×250 MW) and lay the foundation stone of NTPC Talcher Thermal Power Project, Stage-III (2×660 MW) with a total investment of Rs 28,978 Crore during a programme at Sambalpur on 3rd February 2024.

Located in Sundargarh district of Odisha, Darlipali STPP is a pit-head Power Station with Supercritical (highly efficient) Technology and is supplying low-cost power to its beneficiary states, such as Odisha, Bihar, West Bengal, Jharkhand, Gujarat and Sikkim.

The 250 MW project of NTPC-SAIL Power Company Ltd is established in Rourkela Steel Plant (RSP) to provide reliable power for the steel plant which is vital for economic growth.

Further, NTPC is developing Talcher Thermal Power Project, Stage-III within old TTPS plant premises in Angul district of Odisha, which was taken over by NTPC from Odisha State Electricity Board in the year 1995. The old TTPS plant was decommissioned after completing more than 50 years of service to the Nation.

CONFRENCE

The upcoming plant will have highly efficient Ultra Super Critical Technology-based units and approximately three times capacity of the old TTPS plant. While 50% capacity from this project is dedicated to the state of Odisha, other beneficiary states such as Tamil Nadu, Gujarat and Assam will also get low-cost power from this pit-head station.

This project is being constructed with all modern environmental features like efficient electrostatic precipitator, Flue gas desulphurization, bio-mass cofiring, covered storage space for coal and will thus help in lesser Specific Coal Consumption and CO2 emissions.

Besides creating direct and indirect employment opportunities in the region, these projects have contributed to improvement of physical infrastructure such as approach road, drainage, transportation and communication facilities. Various community development initiatives are also being undertaken by NTPC in the surrounding villages in the area of education, drinking water, sanitation, health, women empowerment, rural sports, etc. NTPC has also set up a Medical College cum Hospital in Sundargarh, Odisha.

“ICICI Direct launches Live the AND Life campaign, conceived by Vector Brand Solutions “

Mumbai, 1 February 2024

ICICI Direct has unveiled their latest campaign, Live The AND Life, in collaboration with Vector Brand Solutions, a part of Quotient Ventures.

ICICI Direct Logo

Positioning itself as a one-stop solution for all financial goals, ICICI Direct’s campaign advocates the ‘AND’ lifestyle, encouraging users to pursue multiple aspirations simultaneously, without having to choose between them. The campaign emphasizes inclusivity and balance in one’s financial objectives.

Speaking about the campaign, Mr. Vijay Chandok, Managing Director, ICICI Securities shared, “The campaign is about empowering our customers to ‘Live the AND Life’, which in essence means achieving financial freedom through research-based investing and helping them meet their life goals and dreams. The values that underpin this effort are trust, innovation, expertise and progressiveness. ICICI Direct offers wide range of product and services in Equity, Mutual Funds, Fixed Income and financing options.”

T Gangadhar, Group CEO of Quotient Ventures, added, “We are delighted to announce our debut campaign for ICICI Direct. The ‘Live the AND Life’ campaign marks a strategic shift for the brand, presenting it as a trusted partner for individuals seeking a holistic approach to their financial journey, and promoting a lifestyle that aligns with diverse ambitions”.

“Data Patterns reports growth of 33% in Revenue and 53% in PAT in Q3”

Chennai, February 1, 2024: The Board of Directors at Data Patterns (India) Limited (NSE: DATAPATTNS | BSE: 543428), a vertically integrated Defence and Aerospace electronics solutions provider catering to the indigenously developed defence products industry, today approved the limited review financial results for the quarter ended December 31, 2023.

 performance Highlights

INR in Cr.

Particulars Q3 – FY24 Q3 – FY23 Q2 – FY24 9 months – FY24 9 months – FY23
Total Income       150.81 113.66 119.15      371.26 273.75
Revenue from Operations       139.51 111.81 108.31      337.51 268.35
Operational EBIDTA         60.04 47.04 40.73      128.60 98.47
Profit Before Tax (PBT)         65.72 44.64 46.27      146.87 92.73
Profit After Tax (PAT)         50.97 33.32 33.79      110.59 68.65
Gross Margin 67.69% 66.34% 67.68% 66.24% 65.43%
EBIDTA Margin 43.04% 42.07% 37.61% 38.10% 36.69%

Q3 (2023 – 2024)

  • Total Revenue for Q3 increased by 33% from Rs. 113.66 Cr in quarter ended December 31, 2022 to Rs. 150.81 Cr in quarter ended December 31, 2023 and the revenue from operations increased by 25% in the corresponding period.
  • The Company’s Earnings before Interest, Tax, Depreciation and Amortization (Operational EBIDTA) increased by 28% from INR 47.04 Cr for the quarter ended December 31, 2022 to INR 60.04 Cr in the corresponding quarter ended December 31, 2023
  • Profit Before Tax (PBT) improved by 47% from INR 44.64 Cr in the quarter ended December 31, 2022 to INR 65.72 Cr in the quarter ended December 31, 2023
  • Profit After Tax (PAT) also increased by 53% from Rs. 33.32 Cr in the quarter ended December 31, 2022 to Rs. 50.97 Cr in the quarter ended December 31, 2023.

9 Months (2023 – 2024)

  • Company’s total Revenue for the 9 months ended December 31, 2023 was Rs. 371.26 Cr, an increase of 36% over the 9 months revenue of Rs. 273.75 Cr in FY 2022-23. Revenue from operations increased by 26% from INR 268.35 Cr to Rs. 337.51 Cr in the corresponding 9 months.
  • Operational EBIDTA increased by 31% from INR 98.47 Cr in the 9 months ended December 31, 2022 to INR 128.60 Cr in the corresponding period ended December 31, 2023.
  • Profit Before Tax (PBT) improved by 58% to Rs. 146.87 Cr in the 9 months ended December 31, 2023 as compared to INR 92.73 Cr in the corresponding period ended December 31, 2022.
  • Profit After Tax (PAT) increased by 61% from Rs. 68.65 Cr in the 9 months ended December 31, 2022 to Rs. 110.59 Cr in the 9 months ended December 31, 2023.

ORDER BOOK

  • Orders on hand as on date                         – INR 975.40 Cr
  • Negotiation completed & yet to receive order             – INR    64 Cr
  • Including orders negotiated converted into orders, the order book will be INR 1009 Cr
  • Order book as on April 01, 2023 was Rs. 924.10 Cr

   from the CMD’s Desk

Commenting on the company’s performance, Mr. Srinivasagopalan Rangarajan, Chairman & Managing Director, Data Patterns (India) Limited said, “We are pleased to announce another successful quarter in-line with our expectations. Revenue grew by 25% YoY to Rs 1,395 mn. We have consistently maintained robust margins, with Gross Margins at 68% and EBITDA Margins at 43%. This achievement reflects our unwavering dedication to excellence, innovation, and operational efficiency. Looking ahead, we are committed to ongoing investments in product development to seize the broader opportunities presented by the Government of India’s Defense program.”

SAMCO Continues to Pioneer Momentum Investing in India

Bengaluru, India – 1 Feb 2024 SAMCO Asset Management Private Limited, a leading investment management firm, is delighted to announce the reopening of India’s first actively managed momentum fund – SAMCO Active Momentum Fund. Following its initial launch and in light of the scheme’s proven performance and exceptional response from investors, SAMCO has decided to reopen the fund, providing investors with another opportunity to participate in this highly sought-after investment opportunity.

The SAMCO Active Momentum Fund is built upon the powerful investment strategy, aiming to deliver superior returns for investors by meticulously selecting stocks with momentum characteristics. The fund employs a proprietary momentum-seeking algorithm that identifies breakouts, price leadership, and other crucial momentum indicators.

The fund’s approach is rooted in the belief that by actively leveraging momentum characteristics, such as breakouts and price leadership, it can outperform the market and provide investors with an opportunity to capitalize on prevailing price trends.

Umeshkumar Mehta, Chief Investment Officer (CIO), SAMCO Asset Management Private Limited, said, ” Markets have entered a phase of slower momentum and increased volatility in the wake of upcoming local and global events. We want to use this opportunity to raise gunpowder (i.e. cash) so that when markets begin to accelerate, we are positioned to deploy efficiently to create superior wealth for our investors.”

Mr. Paras Matalia, Co-Fund Manager, SAMCO Asset Management Private Limited, said, “We are excited to reopen SAMCO Active Momentum Fund, providing investors with another opportunity to benefit from momentum investing. By reopening the fund for subscription, we aim to offer investors the chance to position their portfolios strategically and potentially achieve superior risk-adjusted returns.”

Commenting on the reopening, Viraj Gandhi, CEO, SAMCO Asset Management Private Limited, expressed, ” We strongly believe that momentum strategies should be a part of core portfolio allocations of investors seeking wealth creation. In India, active style of momentum investing continues to hold significant potential and offers tremendous advantages. We are pleased to offer investors another chance to participate in this strategy. “

The reopening of SAMCO Active Momentum Fund provides investors with the opportunity to subscribe again and position their portfolios to benefit from the Momentum factor.

“Glenmark partners with Pfizer to launch Abrocitinib in India”

Bengaluru, February 1, 2024: Pfizer and Glenmark Pharmaceuticals Ltd. (Glenmark) have joined hands to launch abrocitinib, a first-of-its-kind oral advanced systemic treatment for moderate-to-severe atopic dermatitis (AD), in India. Developed by Pfizer, abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India and is approved by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regulatory agencies.

When launched in India, it will be co-marketed under the brand names JABRYUS® and CIBINQO® by Glenmark and Pfizer respectively. This collaboration combines the expertise of the companies to offer a groundbreaking treatment for moderate-to-severe AD, with improved efficacy and oral convenience to patients. Abrocitinib (CIBINQO) is available in over 35 markets globally, including the U.S., Japan, and China.

Atopic dermatitis is a chronic skin disease characterized by inflammation of the skin and skin barrier defects 1,2. The persistent itching associated with moderate-to-severe AD disrupts daily life, impacting social interactions, work productivity, and overall well-being. Abrocitinib, a Janus kinase 1 (JAK1) inhibitor, provides rapid itch relief, sustained disease control, and a vastly improved quality of life for patients3.

Meenakshi Nevatia, Country President and Managing Director of Pfizer India stated, “We believe in abrocitinib’s transformative potential. Its approval is a milestone in bringing high-quality treatment for moderate-to-severe atopic dermatitis in India, enabling patients to manage symptoms more effectively. Our collaboration with Glenmark will help leverage the collective strengths and capabilities of our organizations to make this breakthrough therapy available to patients and physicians across our country.”

Alok Malik, President and Business Head ‐ India Formulations, Glenmark Pharmaceuticals Ltd. said, “We are excited to collaborate with Pfizer India for the launch of abrocitinib in the country. The prevalence of atopic dermatitis in India has been reported to be increasing owing to changes in environmental factors with symptoms appearing during the initial years of life in around 80% of patients4. Being a leader in the dermatology therapy in India, this partnership will help us ensure availability of this effective treatment for the Indian patients suffering from moderate-to-severe AD; and further strengthen our position in the dermatology therapy space.”

Prevalence of AD in India

The prevalence of AD has been on the rise over the past three decades with an estimated prevalence of AD of about 10-20% in developed countries3. Approximately 5.9%5 of adults in India are affected by AD, of which 4.4%6 suffer from a severe form of this disease. The symptoms of AD like itching and lack of sleep, lay a significant burden on the patients and their caretakers, affecting multiple aspects including their quality of life and mental health3.

BioAsia 2024 confers the Genome Valley Excellence Award

Hyderabad, 1  February, 2024: The 21st edition of BioAsia – the marquee healthcare and Life Sciences event, organized by the Government of Telangana, has announced that the coveted Genome Valley Excellence Award for the year 2024 will be conferred upon Noble Prize winning Paediatrician and Professor Gregg L. Semenza.

International Advisory Board of BioAsia consisting of personalities of national and international reputation including the likes of Dr. Ajit Shetty (Corporate Vice President Global Operations, Johnson & Johnson USA (retd.) and Chairman Emeritus, Janssen Pharmaceutica, Belgium); Dr. Makarand Jawadekar, (Former Director, Pfizer, US); Dr. Robert Naismith, (Former Chairman, JUJAMA, US), among others have made the final selection of the awardee, in light of his prominent ground-breaking discovery in unveiling the hypoxia-inducible factor 1 (HIF-1 protein), a pivotal discovery controlling gene expression in response to fluctuations in oxygen availability.

Professor L. Semenza is currently the C. Michael Armstrong Professor of Genetic Medicine at Johns Hopkins University School of Medicine, USA. His pioneering work in the field is critical in the treatment of diseases such as cancer, anemia, blinding eye diseases, and cardiovascular disorders.

covid

Professor L.Semenza had discovered how cells can sense and adapt to changing oxygen availability. During the 1990s. he identified a molecular machinery that regulates the activity of genes in response to varying levels of oxygen. The discoveries may lead to new treatments of anemia, cancer, and many other diseases. He received the eminent noble prize in Physiology or Medicine in the year 2019 for the discovery on “how cells sense and adapt to oxygen availability”.

Speaking on the announcement of the 2023 Genome Valley Excellence Award, Mr. D Sridhar Babu, Hon’ble Minister for Industries and IT, Government of Telangana said, “I am thrilled that the award committee has decided to confer the prestigious Genome Valley Excellence Award upon Professor Gregg L. Semenza during the 2024 BioAsia. His groundbreaking discovery in unravelling the scientific mysteries stands as a testament to his unwavering dedication to scientific excellence and innovation. I commend Professor Semenza for his outstanding contributions to the field of molecular biology and extend my best wishes for continued success in his future endeavors. His work serves as an inspiration to aspiring scientists and underscores the transformative power of knowledge in shaping a better tomorrow for humanity. I look forward to welcoming him in Hyderabad and I am sure his visit will energize our scientific community to further Hyderabad’s contribution to biomedical innovation.”

“The Genome Valley Excellence Award has achieved the stature of most eminent awards in the field of life sciences. Year on year distinguished personalities have been presented with this coveted honour. Professor Gregg L. Semenza’s pioneering research has not only deepened our understanding of the intricate mechanisms governing gene expression but also holds immense promise in advancing medical science and improving healthcare outcomes. BioAsia feels honored to host such a renowned personality.” said Mr. Jayesh Ranjan, IAS Principal Secretary (I&C), Government of Telangana.

“The significance of the Genome Valley Excellence Award lies not only in honoring outstanding individuals like Professor Gregg L. Semenza but also in highlighting the collective efforts of the lifesciences community towards advancing scientific knowledge and improving human health. Over the years, the Genome Valley Excellence Award has garnered prominence as a coveted recognition within the lifesciences fraternity and has become synonymous with groundbreaking innovation, cutting-edge research, and transformative impact, inspiring individuals and organizations to strive for excellence in their pursuit of scientific advancement. As we celebrate the remarkable contributions of Professor Semenza and other luminaries honored with the Genome Valley Excellence Award, BioAsia reaffirm its commitment to recognize the efforts of incredible personalities addressing global health challenges and create a better future for humanity.,” said Mr. Shakthi M. Nagappan, CEO, BioAsia and Director of Lifesciences and Pharma, Government of Telangana.

Some of the past Genome Valley Excellence Award winners include Nobel laureates such as Dr. Kurt Wuthrich, Ada Yonath, Harald zur Hausen, Barry Marshall, Martin J Evans, Food Laureates, Lasker Awardees, and eminent leaders like CEO of Novartis Mr. Vas Narasimhan, Richard W. Vague Professor in Immunotherapy and CAR-T cell therapy pioneer, Dr. Carl June, CEO of GAVI Dr. Seth Berkley, among others. Last year, the Genome Valley Excellence award was presented to Dr. Drew Weissman, professor at the Department of Medicine, Perelman School of Medicine, University of Pennsylvania, for his breakthrough pioneering research and development of effective mRNA COVID-19 vaccine that has helped save billions of lives globally. In 2021, it was awarded to Padma Bhushan awardees Dr. Krishna Ella and Mrs. Suchitra Ella of Bharat Biotech International Ltd. for the development and commercialisation of vaccines, including COVID-19 vaccine Covaxin. In 2022, it was awarded to Prof. Robert S. Langer, in light of his pioneering research that has led to the development of the first commercial mRNA vaccines used for variety of infectious diseases.

Medica Superspecialty Hospital celebrates the Brain Tumour Bravehearts

New Delhi, 1st February ’24: Medica Group of Hospitals, the leading private hospital chain in Eastern India, organized an inspiring programme for brain tumour survivors at the hospital today. Recognizing the life-threatening nature of brain tumours and the intricate challenges involved in treating them without causing long-term damage, Medica’s team of highly experienced neurosurgeons have achieved commendable success over the past years. The success is attributed to the unwavering faith and support of patients and their families. During the event, Dr. L.N. Tripathy, Director of Medica Institute of Neurological Diseases (MIND), Senior Consultant, Brain and Spine Surgeon; Dr. Harsh Jain, Senior Consultant – Brain and Spine Surgeon and Dr. Sunandan Basu, Senior Consultant, Brain and Spine Surgeon and ably supported by Dr. Pradip Kumar Mondal, Consultant, Medical & Hemato-Oncology and Dr. Sayan Das, Senior Consultant & Head Radiation Oncology. The programme celebrated the stories of over 20 survivors for their extraordinary journeys, demonstrating that they now not only lead normal and fulfilling lives but also act as sources of inspiration to all other fellow patients.

Brain tumour

During the gathering, Dr. L.N. Tripathy, shared, “In the field of neurosurgery, addressing brain tumours is not merely a surgical procedure; it’s a commitment to not only clinically address the tumour, but also to teat holistically through post-surgical radiation & chemotherapy support and rehabilitation through physiotherapy. We have treated complex brain tumour cases at Medica due to excellent clinical team and the latest technologies. Creation of the support group is to give our patients a platform so that they can share their experiences and give moral support to each other. This group will enable these patients to come back once again to the mainstream of life and lead normal & fulfilling lives.”

Dr. Harsh Jain, shared, “It brings us immense joy to witness everyone present here in a state of well-being and high spirits. At Medica, our commitment is to provide treatment as per global standards in terms of clinical expertise and technology support. We have constituted an internal Tumour Board where we discuss these complex cases across clinicians from concerned disciplines. This board consists of neurosurgeons, neuro-oncologists, neuro-pathologists, and neuro-radiologists, fostering a comprehensive and collaborative approach in addressing these critical cases.”

Dr. Sunandan Basu emphasized, “The collective presence of every survivor in this room highlights that patients need not go elsewhere or other parts of the country for treatments. At Medica we have successfully treated these patients not just from the state but all. Across Eastern India. Their personal journeys serve as powerful testaments to overcoming adversity and standing tall.”

During the meet, one of the male patients, a 33-year-old, shared his journey and expressed, “I have had a long history of impaired vision. In 2018, doctors recommended I should get a CT scan and MRI, which later showed a large pituitary tumour. I had my operation on 13th October’ 18, and I am immensely grateful to the dedicated hospital staff at Medica, who played a pivotal role in my journey. Thanks to their unwavering commitment and expertise, I am now doing well, back to my work, and embracing life with renewed vigor.”

Another male patient, a 38-year-old, shared, “Before being diagnosed with brain tumour, I was plagued by persistent headaches and forgetfulness, which cast a shadow over my daily life. Thanks to the timely intervention and skillful surgery performed on 30th September’22, I am now on the path to recovery. Grateful for the meticulous care and expertise of the doctors, I have not only overcome the challenges but have also returned to my work seamlessly.”

A 35-year-old lady, who had her c-section and brain tumour operation on the same day, in the same operation theatre, shared her journey, “Facing a brain tumour diagnosis during the last trimester of my pregnancy was a nightmare. The problems in vision and recurrent headaches became a serious concern for both me and my unborn child. However, the compassionate efforts of the obstetricians and neurosurgeons, helped me to sail through the adversity in an informed manner where the clinicians kept me updated about the line of treatment at each step. The decision to perform a caesarean section to deliver my baby, followed by a successful brain tumour surgery not only saved my life but also the life of my child. It’s been 4 months since my operation and I do feel happy & confident that I have passed that dark stage of my life and leading a normal life.”

Mr. R. Udayan Lahiry, Managing Director, Medica Group of Hospitals, stated, “As per the National Library of Science, it’s estimated that approximately 10 out of every 100,000 individuals in India are diagnosed with central nervous system tumours, and around 2% of these cases are malignant. Over the past 14 years, our neurosurgeons have consistently achieved high success rates in treating brain tumours. Today, I am overwhelmed to hear the success stories from these survivors. Their feedback is invaluable to us. It strengthens our resolve to continue making a meaningful impact on the lives of those who are suffering.”

Mr. Ayanabh Debgupta, Jt. Managing Director, Medica Group of Hospitals, shared, “The neurosurgery department at Medica has been doing exemplary work since the inception of the hospital. Approximately 1100 complex tumour cases have been operated and this has been possible with the expertise of our clinicians coupled with the latest technologies that we use. Performing such complex cases are now more cohesive with support from the Medica Oncology department as post-surgical Radiation & Chemotherapy services could be availed under one roof. We have not only catered to such patients from Bengal but also from neighbouring North-Eastern states and SAARC countries like Nepal, Bhutan & Bangladesh.”